DNMT3A and myelodysplastic syndrome: Interestingly more patients in the DNMT3A R882 mutant groups showed leukopenia (WBC<2 x 109/L) than the non-R882 groups (31% vs. 24%), and the DNMT3A R882 mutant MDS cases show lower average WBC level than non-R882 mutant cases (mean: 3.0×109/L vs. 4.4×109/L, p=.02) (Table 2).